Calamos Advisors LLC Amgen Inc Transaction History

Calamos Advisors LLC

$16.1 Billion
Q3 2024

A detailed history of Calamos Advisors LLC transactions in Amgen Inc stock. As of the latest transaction made, Calamos Advisors LLC holds 71,485 shares of AMGN stock, worth $18.9 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

71,485

Previous 73,299 2.47%

Holding current value

$18.9 Million

Previous $22.9 Million 0.57%

% of portfolio

0.14%

Previous 0.15%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$309.38 - $337.38 $561,215 - $612,007	-1,814 Reduced 2.47%	71,485 $23 Million
Q2 2024 Jul 25, 2024	SELL	$262.75 - $319.31 $702,330 - $853,515	-2,673 Reduced 3.52%	73,299 $22.9 Million
Q1 2024 May 08, 2024	SELL	$268.87 - $324.56 $513,272 - $619,585	-1,909 Reduced 2.45%	75,972 $21.6 Million
Q4 2023 Jan 31, 2024	SELL	$255.7 - $288.46 $259,791 - $293,075	-1,016 Reduced 1.29%	77,881 $22.4 Million
Q3 2023 Oct 25, 2023	SELL	$218.65 - $271.46 $6,996 - $8,686	-32 Reduced 0.04%	78,897 $21.2 Million
Q2 2023 Jul 28, 2023	SELL	$214.27 - $253.37 $10,284 - $12,161	-48 Reduced 0.06%	78,929 $17.5 Million
Q1 2023 May 03, 2023	SELL	$225.79 - $275.2 $2.23 Million - $2.71 Million	-9,862 Reduced 11.1%	78,977 $19.1 Million
Q4 2022 Jan 25, 2023	SELL	$229.03 - $291.01 $3.59 Million - $4.56 Million	-15,682 Reduced 15.0%	88,839 $0
Q2 2022 Aug 01, 2022	BUY	$230.71 - $256.74 $669,751 - $745,316	2,903 Added 2.86%	104,521 $25.4 Million
Q1 2022 May 03, 2022	BUY	$219.27 - $242.57 $2.98 Million - $3.3 Million	13,589 Added 15.44%	101,618 $24.6 Million
Q4 2021 Feb 01, 2022	BUY	$198.88 - $227.6 $677,783 - $775,660	3,408 Added 4.03%	88,029 $19.8 Million
Q3 2021 Oct 26, 2021	BUY	$212.27 - $248.7 $1.59 Million - $1.86 Million	7,467 Added 9.68%	84,621 $18 Million
Q2 2021 Jul 22, 2021	BUY	$233.58 - $259.14 $4.1 Million - $4.55 Million	17,549 Added 29.44%	77,154 $18.8 Million
Q1 2021 Apr 12, 2021	BUY	$221.91 - $258.6 $408,758 - $476,341	1,842 Added 3.19%	59,605 $14.8 Million
Q4 2020 Jan 27, 2021	SELL	$216.38 - $257.67 $10.2 Million - $12.2 Million	-47,158 Reduced 44.95%	57,763 $13.3 Million
Q3 2020 Oct 26, 2020	SELL	$234.65 - $260.95 $1.24 Million - $1.38 Million	-5,289 Reduced 4.8%	104,921 $26.7 Million
Q2 2020 Jul 27, 2020	SELL	$197.81 - $242.74 $844,648 - $1.04 Million	-4,270 Reduced 3.73%	110,210 $26 Million
Q1 2020 Apr 28, 2020	SELL	$182.24 - $241.7 $8.19 Million - $10.9 Million	-44,917 Reduced 28.18%	114,480 $23.2 Million
Q4 2019 Jan 15, 2020	SELL	$189.21 - $243.2 $234,809 - $301,811	-1,241 Reduced 0.77%	159,397 $38.4 Million
Q3 2019 Oct 21, 2019	BUY	$174.11 - $208.62 $15.7 Million - $18.9 Million	90,392 Added 128.68%	160,638 $31.1 Million
Q2 2019 Aug 07, 2019	BUY	$166.7 - $195.41 $1.63 Million - $1.91 Million	9,777 Added 16.17%	70,246 $12.9 Million
Q1 2019 Apr 12, 2019	SELL	$180.87 - $203.88 $78,859 - $88,891	-436 Reduced 0.72%	60,469 $11.5 Million
Q4 2018 Jan 24, 2019	SELL	$178.4 - $208.25 $7.44 Million - $8.68 Million	-41,681 Reduced 40.63%	60,905 $11.9 Million
Q3 2018 Oct 22, 2018	SELL	$185.29 - $208.89 $4.03 Million - $4.55 Million	-21,772 Reduced 17.51%	102,586 $21.3 Million
Q2 2018 Jul 17, 2018	SELL	$166.05 - $186.51 $2.76 Million - $3.1 Million	-16,606 Reduced 11.78%	124,358 $23 Million
Q1 2018 Apr 13, 2018	SELL	$169.43 - $198.0 $10.4 Million - $12.1 Million	-61,186 Reduced 30.27%	140,964 $24 Million
Q4 2017 Feb 13, 2018	SELL	$168.79 - $188.59 $2 Million - $2.24 Million	-11,860 Reduced 5.54%	202,150 $35.2 Million
Q3 2017 Oct 25, 2017	SELL	$167.29 - $191.0 $2.64 Million - $3.02 Million	-15,801 Reduced 6.88%	214,010 $39.9 Million
Q2 2017 Aug 09, 2017	BUY	N/A	229,811	229,811 $39.6 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.

Account

Calamos Advisors LLC Amgen Inc Transaction History